Related Experiment Video
Updated: Dec 27, 2025

04:22
Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
1.2K
Heterogeneity in Alzheimer's disease
1Suncoast Alzheimer's Disease Laboratories, Department of Psychiatry, University of South Florida, Tampa 33613.
Annals of Medicine
|October 1, 1993
Summary
Genetic mutations in amyloid precursor protein and a chromosome 14 locus are key causes of Alzheimer's disease. Both directly impact the processing and metabolism of amyloid precursor protein, suggesting a unified disease pathway.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder with complex genetic underpinnings.
- Amyloid precursor protein (APP) processing is central to AD pathogenesis.
- Early-onset familial AD has been linked to specific genetic loci.
Purpose of the Study:
- To review and integrate genetic data implicating APP mutations in Alzheimer's disease.
- To examine the role of a major genetic locus on chromosome 14 in early-onset AD.
- To propose a unified model for AD etiology centered on APP metabolism.
Main Methods:
- Literature review and data integration of genetic studies on Alzheimer's disease.
- Analysis of genetic data related to amyloid precursor protein (APP) processing.
- Review of genetic linkage studies identifying loci associated with early-onset AD.
Main Results:
- Mutations within the beta-amyloid segment of APP are confirmed causes of Alzheimer's disease.
- A second major genetic locus for early-onset AD has been identified on chromosome 14.
- This chromosome 14 locus is predicted to involve a protein critical for APP metabolism.
Conclusions:
- Genetic factors influencing APP processing are directly implicated in Alzheimer's disease.
- The identified locus on chromosome 14 likely encodes a protein integral to APP metabolism.
- All forms of Alzheimer's disease are predicted to converge on the pathway of APP metabolism.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment
697
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
697
Dementia
456
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
456

